An analyst wrote that while the delay for risdiplam – prompted by Roche’s submission of additional data – is unfortunate, the timing of the pivotal trials and the patient population guarantee a broad label for the drug, making the company’s decision prudent.

LEAVE A REPLY

Please enter your comment!
Please enter your name here